The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

33 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Full Sequence Amino Acid Scanning of¿-Defensin RTD-1 Yields a Potent Anthrax Lethal Factor Protease Inhibitor.EBI
State University of New York
Probing the S2' Subsite of the Anthrax Toxin Lethal Factor Using Novel N-Alkylated Hydroxamates.EBI
University of Minnesota
Exploring the influence of the protein environment on metal-binding pharmacophores.EBI
University of California
Small molecule inhibitors of anthrax lethal factor toxin.EBI
Microbiotix
D-proline-based peptidomimetic inhibitors of anthrax lethal factor.EBI
TBA
Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.EBI
Panthera Biopharma
Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.EBI
Microbiotix
Amiodarone and bepridil inhibit anthrax toxin entry into host cells.EBI
University of California
Inhibitors of anthrax lethal factor based upon N-oleoyldopamine.EBI
Purdue University
Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.EBI
Microbiotix
Antidotes to anthrax lethal factor intoxication. Part 2: structural modifications leading to improved in vivo efficacy.EBI
Panthera Biopharma
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.EBI
University of California
Antidotes to anthrax lethal factor intoxication. Part 1: Discovery of potent lethal factor inhibitors with in vivo efficacy.EBI
Panthera Biopharma
In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin.EBI
National Institute of Allergy and Infectious Diseases
Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors.EBI
Institute For Medical Research
Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.EBI
Institute For Medical Research
Inhibitors of anthrax lethal factor.EBI
Purdue University
5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry.EBI
Danylo Halytsky Lviv National Medical University
Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors.EBI
Government College Women University
Zinc enzymes in medicinal chemistry.EBI
Hefei University of Technology
In-cell production of a genetically-encoded library based on the θ-defensin RTD-1 using a bacterial expression system.EBI
University of Southern California
Small molecule inhibitors of anthrax edema factor.EBI
Hawaii Biotech
Pyrazole compoundBDB
Sumitomo Dainippon Pharma
N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamineBDB
Glucox Biotech
Bicyclic heterocycles as FGFR inhibitorsBDB
Incyte Holdings
Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of diseaseBDB
Novartis
Multiple kinase pathway inhibitorsBDB
Tolero Pharmaceuticals
Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitorsBDB
Almac Discovery
Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.BDB
University of Auckland
Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.BDB
Boehringer Ingelheim Pharmaceuticals